The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.
In this trial (KEYNOTE-427), treatment of patients with advanced non-clear cell renal cell carcinoma (RCC) with pembrolizumab monotherapy demonstrated an overall objective response rate of around 25% for papillary RCC patients and almost 35% for patients with unclassified RCC.
Pembrolizumab is currently only available for the treatment of advanced kidney cancer through taking part in a clinical trial. It is yet to be approved for use within the UK and the NHS by the MHRA and NICE respectively.
Read more in Cancer Therapy Advisor here